Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Karuna Therapeutics, Inc.
| Metric | Karuna Therapeutics, Inc. Healthcare |
|---|---|
| Quality Score | 40 / 100 |
| Revenue (latest) | $654,000 |
| Net income (latest) | −$434M |
| Operating margin | −75654.0% |
| Net margin | −66311.9% |
| Return on equity | −34.6% |
| Return on assets | −32.5% |
| Return on capital (ROCE) | −39.0% |
| Debt / equity | 0.07× |
| Revenue growth (YoY) | −93.9% |
| Altman Z″ (distress) | 17.27 |
| Accruals / assets | −3.6% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.